Xizang Haisco Pharmaceutical Group Co Ltd (002653) - Total Liabilities
Based on the latest financial reports, Xizang Haisco Pharmaceutical Group Co Ltd (002653) has total liabilities worth CN¥3.06 Billion CNY (≈ $448.29 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Xizang Haisco Pharmaceutical Group Co Lt (002653) long-term investment share to see how much of total assets are deployed in long-term investments.
Xizang Haisco Pharmaceutical Group Co Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Xizang Haisco Pharmaceutical Group Co Lt's balance sheet.
Xizang Haisco Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Xizang Haisco Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sociedad Química y Minera de Chile S.A.
SN:SQM-B
|
Chile | CL$6.19 Billion |
|
New York Times Company
NYSE:NYT
|
USA | $936.99 Million |
|
LIG Nex1 Co Ltd
KO:079550
|
Korea | ₩5.90 Trillion |
|
SK TELECOM CO.LTD.ADR 5/9
F:KMBA
|
Germany | €17.15 Trillion |
|
The AES Corporation
NYSE:AES
|
USA | $43.46 Billion |
|
Nexchip Semiconductor Corp. A
SHG:688249
|
China | CN¥25.06 Billion |
|
News Corp A
NASDAQ:NWSA
|
USA | $6.31 Billion |
|
Eurofins Scientific SE
PA:ERF
|
France | €7.40 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Xizang Haisco Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002653 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xizang Haisco Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual total liabilities of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.72 Billion ≈ $398.41 Million |
+4.87% |
| 2024-12-31 | CN¥2.60 Billion ≈ $379.90 Million |
+4.59% |
| 2023-12-31 | CN¥2.48 Billion ≈ $363.25 Million |
-14.82% |
| 2022-12-31 | CN¥2.91 Billion ≈ $426.45 Million |
+39.77% |
| 2021-12-31 | CN¥2.09 Billion ≈ $305.11 Million |
-2.80% |
| 2020-12-31 | CN¥2.15 Billion ≈ $313.92 Million |
-19.31% |
| 2019-12-31 | CN¥2.66 Billion ≈ $389.04 Million |
+12.10% |
| 2018-12-31 | CN¥2.37 Billion ≈ $347.03 Million |
+10.90% |
| 2017-12-31 | CN¥2.14 Billion ≈ $312.94 Million |
+42.72% |
| 2016-12-31 | CN¥1.50 Billion ≈ $219.27 Million |
+39.92% |
| 2015-12-31 | CN¥1.07 Billion ≈ $156.71 Million |
+39.53% |
| 2014-12-31 | CN¥767.55 Million ≈ $112.32 Million |
+44.75% |
| 2013-12-31 | CN¥530.24 Million ≈ $77.59 Million |
+122.33% |
| 2012-12-31 | CN¥238.49 Million ≈ $34.90 Million |
+107.48% |
| 2011-12-31 | CN¥114.95 Million ≈ $16.82 Million |
-34.98% |
| 2010-12-31 | CN¥176.79 Million ≈ $25.87 Million |
-17.47% |
| 2009-12-31 | CN¥214.22 Million ≈ $31.35 Million |
+54.41% |
| 2008-12-31 | CN¥138.73 Million ≈ $20.30 Million |
-- |
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more